The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

(Reuters) -AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...

Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder that causes muscle weakness, numbness, and even paralysis.

Sepsis, a life-threatening condition caused by the body's extreme response to infection, is a silent killer in India. While cancer receives significant attention in terms of research, treatment ...